Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
An overview of the mechanism of action, dosing, clinical indications, and toxicities of the glycopeptide vancomycin is provided. Emerging gram-positive bacterial resistance to antimicrobials and its mechanisms are reviewed. Strategies to control emergence of resistance are proposed. Newer antimicrobial agents with activity against vancomycin-resistant organisms are now available and play a critical role in the treatment of life-threatening infections.
Division of Infectious Diseases, Wayne State University-Detroit Medical Center, 4201 St. Antoine UHC 2B, Detroit, MI 48201, USA. tlundstrom@dmc.org
Tammy S
TS
Lundstrom
Jack D
JD
Sobel
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017576:Daptomycin / Q000494:pharmacology* / Q000627:therapeutic use; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D014640:Vancomycin / Q000494:pharmacology*; D014769:Virginiamycin / Q000494:pharmacology* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D014640:Vancomycin; D017576:Daptomycin